Paratope-PLUS® IP CDR-Scanning Service
Experimental Data to Enable Your Antibody Patent Claims
A strategy developed in collaboration with patent attorneys — purpose-built for patent enablement. Published in Nature Biotechnology (Banik et al., 2025).
USPTO-Accepted
for structure based antibody genus claims
§112 Compliant
Fulfills enablement and written description
Generates Novel IP
Dataset informs multi-parametric engineering insights
What the Data Package Delivers
A Documented Precedent. The CDR-scanning strategy has cleared USPTO examination — giving you a documented precedent to reference, not merely a theoretical approach. (US Patent 12,545,726, issued February 2026.) We’ll supply draft claims based on the same approach.
A Strong Experimental Foundation. You’ll receive expression and binding data for all 19 possible amino acid substitutions at each CDR position, identifying the common structural feature that defines the genus and every functionally equivalent variant. This is the experimental reduction to practice that enablement and written description now demand.
One Dataset for Multiple Uses. The same experimental data that supports structure-based genus claims also provides antibody engineering insights into variants with improved binding and other properties — the basis for independent composition claims that expand an antibody IP portfolio beyond the original sequence.
Your Trusted Lab Partner for Patent Filings
Our scientists developed Paratope-PLUS IP in collaboration with patent attorneys and IP experts, so the data package is designed around what examiners need, not just what scientists measure.
We supply the complete CDR-scanning dataset. You use it to develop fully enabled, structure-based genus claims that withstand USPTO scrutiny; increase the value of your antibody IP portfolio; and mitigate the risk of post-grant challenges.
- Developed in collaboration with patent attorneys and IP experts
- Delivered with draft claim language
- Published in Nature Biotechnology (Banik et al., 2025)
- State-of the art lab facilities for high-throughput mutagenesis and screening
- Philadelphia-based, US-owned
- Fee-for-service model — all IP remains with you
- Rigorous data security and confidentiality protocols
Proven in Practice: US Patent 12,545,726
Integral Molecular applied CDR-scanning to our own GPRC5D therapeutic antibody program, systematically testing all 19 possible amino acid substitutions at each CDR residue to identify the common structural feature of the antibody genus and the full set of permissible variants.
The result: a granted US patent with structure-based genus claims, accepted by the USPTO.
Ready to discuss your project?
Our scientific team works directly with patent attorneys and in-house IP counsel to scope projects and deliver data packages designed for patent enablement.
Integral Molecular does not guarantee patent allowance. USPTO acceptance of specific claims depends on prosecution strategy and examiner review.